Analyst Price Target is $53.71
▲ +38.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is $53.71, with a high forecast of $60.00 and a low forecast of $47.00. The average price target represents a 38.08% upside from the last price of $38.90.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Royalty Pharma. This Buy consensus rating has held steady for over two years.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.